Moneycontrol
HomeNewsBusinessEconomyCentre gives Rs 15,000 crore in long-term loans to states for capex spending
Trending Topics

Centre gives Rs 15,000 crore in long-term loans to states for capex spending

The loans include Rs 5,000 crore to incentivise states to monetise their assets and divest their PSUs.

April 30, 2021 / 16:38 IST
Story continues below Advertisement

The Finance Ministry on April 30 said it would provide Rs 15,000 crore worth of long-term loans to states for their capital expenditure needs. This would include around Rs 5,000 crore for incentivising states to carry out monetisation of their idle assets and divest their companies, an official statement said.

“The Ministry of Finance has decided to provide an additional amount of up to Rs 15,000 crore to States as interest free 50-year loan for spending on capital projects. The Department of Expenditure has issued fresh guidelines in this regard on the “Scheme of Financial Assistance to States for Capital Expenditure” for the financial year 2021-22,” said the press release.

Story continues below Advertisement

This move follows a similar step taken last year, when as part of the ‘Aatmanirbhar Bharat’ set of announcements, the Centre provided Rs 12,000 crore as a 50-year loan to states to enable them to carry out capital expenditure work in a pandemic-hit year.

As part of her capital stimulus push in the budget, Finance Minister Nirmala Sitharaman had said: “We would also be providing more than Rs 2 lakh crore to states and autonomous bodies for their capital expenditure. We will also work out specific mechanisms to nudge states to spend more of their budget on creation of infrastructure.”

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show